Sutimlimab
Sutimlimab
Sutimlimab (pronounced soo-tim-li-mab) is a humanized monoclonal antibody designed for the treatment of cold agglutinin disease (CAD). It is developed by Sanofi, a French multinational pharmaceutical company.
Etymology
The name "Sutimlimab" is derived from the International Nonproprietary Names (INN), where "su-" refers to its source (human), "-ti-" denotes its target (immune system), "-lim-" signifies its species (humanized immunoglobulin), and "-mab" indicates its class (monoclonal antibody).
Mechanism of Action
Sutimlimab works by inhibiting a protein called C1s, which is a part of the complement system, a group of proteins that move freely through your bloodstream. The proteins of the complement system work with your immune system and play a role in the development of inflammation.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Cold Agglutinin Disease (CAD): A rare type of autoimmune hemolytic anemia where the body's immune system mistakenly attacks and destroys its own red blood cells.
- Complement System: A part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promote inflammation, and attack the pathogen's cell membrane.
- C1s: A protein that in humans is encoded by the C1S gene. It is a subcomponent of the C1-complex of complement proteins.
See Also
External links
- Medical encyclopedia article on Sutimlimab
- Wikipedia's article - Sutimlimab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski